What's Happening?
Swiss biotech Pharvaris has reported positive data from a Phase 3 trial of its extended-release formulation of deucrictibant, a bradykinin B2 receptor antagonist, for hereditary angioedema (HAE). The drug achieved an 83% reduction in monthly HAE attacks
compared to placebo in the CHAPTER-3 study, which included all three types of HAE. This pivotal trial win sets the stage for marketing applications in the U.S. next year. Pharvaris has also filed an oral formulation of deucrictibant for on-demand treatment of HAE attacks with the U.S. FDA in June, with a decision expected by April 23, 2027. Analysts project peak sales for deucrictibant could reach $1 billion to $2 billion if both formulations are approved.
Why It's Important?
The positive Phase 3 results for deucrictibant are highly significant for the HAE community, which still seeks improved disease control and reduced treatment burden. HAE is characterized by unpredictable and debilitating swelling attacks, and an effective, well-tolerated oral therapy with injectable-like efficacy would be a major advancement. While there are existing FDA-approved oral therapies for HAE, deucrictibant's efficacy, tolerability, and oral administration position it as a potentially important addition to clinical practice, supporting individualized treatment strategies. The drug's ability to reduce attacks across all HAE types, including the less common type 3, further broadens its potential impact. This development could significantly improve the quality of life for HAE patients by offering a convenient and highly effective prophylactic option.
What's Next?
Pharvaris plans to submit marketing applications for the extended-release formulation of deucrictibant in the U.S. next year, following the successful CHAPTER-3 trial. The FDA decision for the on-demand oral formulation, filed in June, is anticipated by April 23, 2027. The company is also conducting CHAPTER-4, an open-label long-term extension study for deucrictibant XR, and CREAATE, a Phase 3 study investigating its potential in acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). These ongoing studies will provide further data on the drug's long-term safety and efficacy, as well as its potential in related conditions. The focus will now be on the regulatory review processes and the subsequent commercialization strategy.
Beyond the Headlines
The emergence of deucrictibant highlights the ongoing innovation in the treatment of rare diseases like HAE. The development of highly effective oral therapies represents a significant shift from traditional injectable treatments, offering greater convenience and potentially improving patient adherence. This trend towards less burdensome treatment regimens can empower patients to better manage their conditions and lead more normal lives. Furthermore, the competitive landscape in HAE treatment, with multiple drugs vying for market share, encourages continuous improvement in efficacy, safety, and patient experience. The potential for deucrictibant to achieve blockbuster status also underscores the commercial viability of developing therapies for niche indications, driving further investment in rare disease research and development.
